Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The trial will enroll up to 42 patients in Finland across four cohorts
Subscribe To Our Newsletter & Stay Updated